Company Overview and News

1
Roivant Licenses Diabetes Drug From Ligand Pharma

2018-03-07 biospace
Ligand Pharmaceuticals Inc. is licensing LGD-6972, a glucagon receptor antagonist (GRA), to Roivant Sciences GmbH for $20 million upfront. The drug will be developed by Roivant’s recently founded Metavant Sciences, now dubbed RVT-1502, as well as imeglimin (RVT-1501).
Upvote Downvote

 
Ooivant Licenses Diabetes Drug From Ligand Pharma

2018-03-07 biospace
Ligand Pharmaceuticals Inc. is licensing LGD-6972, a glucagon receptor antagonist (GRA), to Roivant Sciences GmbH for $20 million upfront. The drug will be developed by Roivant’s recently founded Metavant Sciences, now dubbed RVT-1502, as well as imeglimin (RVT-1501).
Upvote Downvote

 
Daily, Long-Acting Oral Insulin Tablet Provides Comparable Glycemic Control to Insulin Glargine Injection in Patients with Type 2 Diabetes

2017-06-13 prnewswire
SAN DIEGO , June 13, 2017 /PRNewswire-USNewswire/ -- A long-acting, oral insulin tablet has been found to safely improve glycemic control as effectively as the common, injected insulin glargine in people with Type 2 diabetes, according to the study, "Efficacy and Safety of Oral Basal Insulin: Eight-Week Feasibility Study in People with Type 2 Diabetes (T2DM)," presented today at the American Diabetes Association's 77th Scientific Sessions® at the San Diego Convention Center.
Upvote Downvote

 
Poxel Rockets After Diabetes Med Hits Goals in Mid-Stage Study

2017-05-04 biospace
LYON, France--(BUSINESS WIRE)--POXEL SA (Euronext – POXEL - FR0012432516), a biopharmaceutical company focused on the development of innovative drugs to treat metabolic diseases, including type 2 diabetes, announced today positive top line Phase 2b data results for Imeglimin for the treatment of type 2 diabetes in Japan.
Upvote Downvote

 
BRIEF-Nokia expands patent litigation against Apple in Asia, Europe and U.S.

2016-12-22 feeds.reuters
* Nokia -"filed further complaints alleging that apple products infringe a number of nokia patents, expanding its litigation originally announced on dec 21" Source text for Eikon: Further company coverage:
Upvote Downvote

 
BRIEF-Basic Energy Services to continue listing new shares of common stock

2016-12-22 feeds.reuters
* Basic Energy Services Inc. to continue listing new shares of common stock and resume trading under ticker "BAS" following emergence from chapter 11 reorganization
Upvote Downvote

 
UPDATE 1-U.S. 30-year mortgage rates rise to highest since 2014 - Freddie Mac

2016-12-22 reuters
* Net income for fiscal Q4 ended september 30, 2016 was approximately $1 million compared to a net loss of approximately $1.3 million-SEC filing
Upvote Downvote

 
BRIEF-Poxel SA says CFO Eric Massou resigned

2016-12-22 feeds.reuters
* Poxel SA says Poxel has identified a new CFO, and an announcement will be made during Q1 of 2017 Source text for Eikon: Further company coverage:
Upvote Downvote

 
BRIEF-Luxottica renews Ralph Lauren licence accord for 10 years

2016-12-22 feeds.reuters
* Renews licence agreement with Ralph Lauren until March 31, 2027 Further company coverage: (Reporting by Milan newsroom)
Upvote Downvote

 
BRIEF-Nokia esays xpands patent litigation against Apple in Asia, Europe and the U.S.

2016-12-22 feeds.reuters
* Nokia corp says has filed further complaints alleging that apple products infringe a number of Nokia patents, expanding its litigation originally announced on december 21.
Upvote Downvote

 
BRIEF-Gee Group Q4 revenue rose 75 percent to $21.8 million

2016-12-22 feeds.reuters
* Net income for fiscal Q4 ended september 30, 2016 was approximately $1 million compared to a net loss of approximately $1.3 million-SEC filing
Upvote Downvote

 
Poxel completes patient enrollment for diabetes drug phase IIb trials in Japan

2016-07-01 biospectrumasia
It's fast, free and easy to sign in with Facebook, Google, or Yahoo. Be connected on your terms - we won't share anything without your permission
Upvote Downvote

Related Articles

RDHL: Redhill Biopharma Ltd (OTC:REDIF) Analysis and Research Report

2018-04-18 - Asif

History and Development of the Company The company's legal and commercial name is RedHill Biopharma Ltd. The company's company was incorporated on August 3, 2009, and was registered as a private company limited by shares under the laws of the State of Israel. The company's principal executive offices are located at 21 Ha’arba’a Street, Tel Aviv, Israel. In February 2011, the company completed its initial public offering in Israel, pursuant to which the company issued 14,302,300 Ordinary Shares, and 7,151,150 tradable Series 1 Warrants to purchase 7,151,150 Ordinary Shares for aggregate gross proceeds of approximately $14 million. On December 27, 2012, the company completed the listing of its ADSs on the NASDAQ Capital Market. The company's Ordinary Shares are traded on the Tel-Aviv Stock Exchange under the symbol “RDHL,” and its ADSs are traded on the NASDAQ Capital Market under the same symbol "RDHL". The company's capital expenditures for the years ended December 31, 2...

SCYX: SCYNEXIS Analysis and Research Report

2018-04-16 - Asif

Overview SCYNEXIS, Inc. is a biotechnology company committed to positively impacting the lives of patients suffering from difficult-to-treat and often life-threatening infections by delivering innovative anti-infective therapies. SCYNEXIS is developing its lead product candidate, SCY-078, as the first representative of a novel oral and intravenous (IV) triterpenoid antifungal family in clinical development for the treatment of several serious fungal infections, including invasive candidiasis, invasive aspergillosis, refractory invasive fungal infections and vulvovaginal candidiasis (VVC). SCY-078 is a structurally distinct glucan synthase inhibitor that has been shown to be effective in vitro and in vivo against a broad range of human fungi pathogens such as Candida and Aspergillus species, including multidrug-resistant strains, as well as Pneumocystis species. Candida and Aspergillus species are the fungi responsible for approximately 85% of all invasive fungal infections in t...

ENRT: Enertopia Corp (CNSX:TOP) Analysis and Research Report

2018-04-16 - Asif

Business History Enertopia Corp. was formed on November 24, 2004 under the laws of the State of Nevada and commenced operations on November 24, 2004. From inception until April 2010, the company were primarily engaged in the acquisition and exploration of natural resource properties. Beginning in April 2010, the company began its entry into the renewable energy sector by purchasing an interest in a solar thermal design and installation company. In late summer 2013, the company began its entry into medicinal marijuana business. During its 2014 fiscal year end its activities in the clean energy sector were discontinued. During fiscal 2015 its activities in the Medicinal Marijuana sector were discontinued. During fiscal 2016 its activities in the Women’s personal healthcare sector were discontinued. The Company is actively pursuing business opportunities in the resource sector, whereby the company signed a definitive agreement for a Lithium Brine Project in May 2016. In May ...

FB: Facebook Analysis and Research Report

2018-04-15 - Asif

Overview The company's mission is to give people the power to build community and bring the world closer together. The company's top priority is to build useful and engaging products that enable people to connect and share with friends and family through mobile devices, personal computers, and other surfaces. The company also help people discover and learn about what is going on in the world around them, enable people to share their opinions, ideas, photos and videos, and other activities with audiences ranging from their closest friends to the public at large, and stay connected everywhere by accessing its products, including: Facebook enables people to connect, share, discover, and communicate with each other on mobile devices and personal computers. There are a number of different ways to engage with people on Facebook, the most important of which is News Feed which displays an algorithmically-ranked series of stories and advertisements individualized for each pers...

VSTM: Verastem Analysis and Research Report

2018-04-12 - Asif

Business Overview Verastem is a biopharmaceutical company focused on developing and commercializing drugs to improve the survival and quality of life of cancer patients. The company's most advanced product candidates, duvelisib and defactinib, utilize a multi-faceted approach to treat cancers originating either in the blood or major organ systems. Verastem is currently evaluating these compounds in both preclinical and clinical studies as potential therapies for certain cancers, including leukemia, lymphoma, lung cancer, ovarian cancer, mesothelioma, and pancreatic cancer. The company believe that these compounds may be beneficial as therapeutics either as single agents or when used in combination with immuno-oncology agents or other current and emerging standard of care treatments in aggressive cancers that are poorly served by currently available therapies. Duvelisib targets the Phosphoinositide 3-kinase (PI3K) signaling pathway. The PI3K signaling pathway plays a centr...